NCT01231581 - Study of GSK1120212 Plus Gemcitabine vs Placebo Plus Gemcitabine in Metastatic Pancreatic Cancer | Biotech Hunter

Enrollment

160

Participants

Timeline

Start Date

August 31, 2010

Primary Completion Date

April 30, 2012

Study Completion Date

February 28, 2013

Conditions

Cancer

Interventions

DRUG

GSK1120212

administered orally starting on day 1 followed by a continuous daily dosing of 2.0 mg

DRUG

Gemcitabine

Intravenous gemcitabine infused over 30 minutes weekly for 7 weeks followed by one week of rest from treatment. Subsequent cycles will consist of 1000 mg/m2 intravenous infusion over 30 minutes on days 1, 8, and 15 followed by 1 week of rest from treatment for each 28-day treatment period.

DRUG

Placebo

administered orally starting on day 1 followed by a continuous daily dosing of 2.0 mg

Trial Locations (7)

112

GSK Investigational Site, Taipei

333

GSK Investigational Site, Gueishan Township,Taoyuan County

704

GSK Investigational Site, Tainan City

110-744

GSK Investigational Site, Seoul

120-752

GSK Investigational Site, Seoul

135-710

GSK Investigational Site, Seoul

138-736

GSK Investigational Site, Seoul